USD10
SRRK Ações
Conheça: Scholar Rock HoldingScholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
USD10
SRRK Ações
Conheça: Scholar Rock HoldingScholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Estatísticas
JANELA DE NEGOCIAÇÃO
Fechado
ABRE ÀS
Não há dados suficientes
CAPITALIZAÇÃO DE MERCADO
US$ 5,75 bi
PREÇO DE ABERTURA
US$ 48,49
MÍNIMA (1 ano)
US$ 22,71
MÁXIMA (1 ano)
US$ 50,50
MÍNIMA (24 horas)
US$ 47,96
MÁXIMA (24 horas)
US$ 50,36
VOLUME (24 horas)
US$ 2,03 mi
23,05%
Histórico de preços
Time | Price | Change |
|---|---|---|
Hoje | US$ 48,49 | |
1 dia | US$ 50,01 | 0,00% |
1 semana | US$ 42,53 | |
1 mês | US$ 47,43 | |
1 ano | US$ 26,04 |